Dong S, Dong W, Tan Y, Xiao Q, Wang T
Front Oncol. 2024; 14:1370901.
PMID: 38690167
PMC: 11059057.
DOI: 10.3389/fonc.2024.1370901.
Patil T, Staley A, Nie Y, Sakamoto M, Stalker M, Jurica J
JTO Clin Res Rep. 2024; 5(2):100637.
PMID: 38361741
PMC: 10867444.
DOI: 10.1016/j.jtocrr.2024.100637.
Han Y, Yu Y, Miao D, Zhou M, Zhao J, Shao Z
JTO Clin Res Rep. 2024; 5(2):100630.
PMID: 38361739
PMC: 10867448.
DOI: 10.1016/j.jtocrr.2023.100630.
Laface C, Maselli F, Santoro A, Iaia M, Ambrogio F, Laterza M
Pharmaceutics. 2023; 15(6).
PMID: 37376053
PMC: 10302309.
DOI: 10.3390/pharmaceutics15061604.
Gomatou G, Syrigos N, Kotteas E
Cancers (Basel). 2023; 15(3).
PMID: 36765799
PMC: 9913144.
DOI: 10.3390/cancers15030841.
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.
Fu K, Xie F, Wang F, Fu L
J Hematol Oncol. 2022; 15(1):173.
PMID: 36482474
PMC: 9733018.
DOI: 10.1186/s13045-022-01391-4.
BCL6-SPECC1L: A Novel Fusion Gene in Nasopharyngeal Carcinoma.
Fang S, Xia T, Fu J, Li T, Zhong Q, Han F
Technol Cancer Res Treat. 2022; 21:15330338221139981.
PMID: 36412101
PMC: 9706053.
DOI: 10.1177/15330338221139981.
Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon G719D/L861Q mutations and an acquired novel - fusion.
Ou L, Tang Y, Deng Y, Guo L, He Q, He T
Front Oncol. 2022; 12:911362.
PMID: 35957915
PMC: 9360523.
DOI: 10.3389/fonc.2022.911362.
Cytospin-A Regulates Colorectal Cancer Cell Division and Migration by Modulating Stability of Microtubules and Actin Filaments.
Fan F, Roszik J, Xia L, Ghosh S, Wang R, Ye X
Cancers (Basel). 2022; 14(8).
PMID: 35454887
PMC: 9026928.
DOI: 10.3390/cancers14081977.
Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel Fusion.
Ma Q, Kong L, Zhong D
Front Oncol. 2022; 12:804330.
PMID: 35237515
PMC: 8883050.
DOI: 10.3389/fonc.2022.804330.
Molecular Mechanism of EGFR-TKI Resistance in -Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.
Reita D, Pabst L, Pencreach E, Guerin E, Dano L, Rimelen V
Cancers (Basel). 2021; 13(19).
PMID: 34638411
PMC: 8507869.
DOI: 10.3390/cancers13194926.
Emerging oncogenic fusions other than , , , and in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.
Suda K, Mitsudomi T
Transl Lung Cancer Res. 2021; 9(6):2618-2628.
PMID: 33489822
PMC: 7815361.
DOI: 10.21037/tlcr-20-186.
Recurrent fusions in pediatric sarcoma and brain tumors.
Khuong-Quang D, Brown L, Wong M, Mayoh C, Sexton-Oates A, Kumar A
Cold Spring Harb Mol Case Stud. 2020; 6(6).
PMID: 33144287
PMC: 7784491.
DOI: 10.1101/mcs.a005710.
Identification of prognostic markers of lung cancer through bioinformatics analysis and in vitro experiments.
Ling B, Liao X, Huang Y, Liang L, Jiang Y, Pang Y
Int J Oncol. 2019; 56(1):193-205.
PMID: 31789390
PMC: 6910184.
DOI: 10.3892/ijo.2019.4926.
